MedTrace Logo

Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients

NCT04143451 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4000

Last updated 2021-04-28

No results posted yet for this study

Summary

To compare the safety and clinical efficacy (death, overall hospitalization, hospitalization for influenza or pneumonia) of ID QIV delivered via an intradermal device with imiquimod cream pretreatment with conventional intramuscular (IM) standard dose QIV and IM high-dose TIV

Conditions

Interventions

BIOLOGICAL

Vaxigrip tetra

quadrivalent influenza vaccine

BIOLOGICAL

Fluzone high-dose

high-dose trivalent influenza vaccine

DRUG

Aldara 5% Topical Cream

imiquimod cream

DRUG

Aqueous cream BP

inactive aqueous cream

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Ivan FN Hung, MD FRCP · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-23
Primary Completion
2022-09-30
Completion
2023-03-31
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04143451 on ClinicalTrials.gov